Mopristad 5

Mosapride citrate is a selective 5-HT4 receptor agonist. Mopristad 5 stimulates 5-HT4 receptors in the gastrointestinal nerve plexus, which increase the release of acetylcholine, resulting in enhancement of gastrointestinal motility and gastric emptying.

Pack size Box of 30 tablets, 60 tablets
Shelf-life 24 months
Composition Mosapride citrate (as mosapride citrate dihydrate)
Dosage forms and strengths Film-coated tablet: 5 mg
Product code :



Treatment gastrointestinal symptoms (heartburn, nausea/vomiting) associated with functional dyspepsia (chronic gastritis).


  • Adults: 15 mg of mosapride citrate (3 tablets) is usually administered daily in 3 divided oral doses before or after meals.
  • Elderly: Since in the elderly patients their physiological function in the kidneys and the liver are reduced in general, this drug should be administered with care by monitoring patients’ condition. If any adverse reactions are found, appropriate measures such as reducing the dose (e.g. to 7.5 mg daily) should be given.
  • Paediatric (under 18 years of age): Safety of mosapride citrate in children has not been established. This drug should not be recommended for use in this population.


Oral use. The tablets can be taken before or after meals.

Patients with a history of hypersensitivity to mosapride citrate or to any of the ingredients.

1% to less than 5%

  • Edema;
  • Eosinophilia, leukopenia;
  • Diarrhea/loose stools, dry mouth, abdominal pain, nausea/vomiting, taste abnormality;
  • Elevations of AST (GOT), ALT (GPT), ALP, gamma-GTP and bilirubin;
  • Palpitation;
  • Dizziness/light-headedness, headache;
  • Malaise, elevation of triglyceride.

Frequency unknown

  • Rash, urticaria;
  • Feeling of abdominal distension, numbness of mouth (including tongue and lip, etc.);
  • Tremor.
  • If any improvement of gastrointestinal symptoms is not observed after the administration for a given period of time (usually for 2 weeks), this drug should be discontinued.
  • This drug contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
  • This drug should not be used in pregnant women, women who may possibly be pregnant, only if the expected therapeutic benefits outweigh the possible risks associated with the treatment.
  • Administration of this drug to nursing mothers should be avoided. If administration is essential, nursing mothers should discontinue breast feeding during the treatment.
  • No study in effects of the drug on ability to drive and use machines have been done. Patients should be aware of how they react to drug before driving or operating machinery.